IMBECU   20882
INSTITUTO DE MEDICINA Y BIOLOGIA EXPERIMENTAL DE CUYO
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
PROGNOSTIC IMPLICATION OF HSP70 (HSPA) IN BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT ANTHRACYCLINE BASED CHEMOTHERAPY
Autor/es:
NADIN SB; MAYRA L. SOTTILE; MM MONTT GUEVARA; GAUNA G; PEDRO DAGUERRE; MARCELA LEUZZI; FRANCISCO E. GAGO; JORGE IBARRA; DANIEL R. CIOCCA; LAURA M. VARGAS-ROIG
Lugar:
Sheffield
Reunión:
Congreso; VI International Congress on Stress Proteins in Biology and Medicine; 2013
Institución organizadora:
Cell Stress Society International
Resumen:
Over the last years, many efforts have been made in searching molecular markers of drug resistance. Heat shock proteins (HSPs) are expressed at high levels in mammary tumor cells and they have been implicated with resistance to antineoplasic drugs. Neoadjuvant chemotherapy is used in patients with locally advanced breast cancer to reduce the tumor size before surgery. However, there is little evidence on the value of the HSPs as prognostic markers in breast tumors treated with anthracycline based chemotherapy. We evaluate by immunohistochemistry the expression of HSP27 and HSP70 in serial biopsies from locally advanced breast cancer patients (n= 60) treated with doxorubicin (DOX) or epirubicin (EPI) based monochemotherapy. The serial biopsies were taken at days 1, 3, 7, 21, and compared with the pre-chemotherapy and with the surgical biopsies. Nuclear HSP27 and HSP70 expression was high in invasive cells after DOX/EPI administration (P11% of the tumor cells) evaluated in the post-chemotherapy biopsies was associated with better DFS (P=0.023 and P=0.0169, respectively). Our study indicates that high HSP70 expression may be a useful prognosis marker in breast cancer patients treated with neoadjuvant DOX or EPI chemotherapy, indicating the requirement to change the administered drugs after surgery (in this study we used Cyclophosphamide, Methotrexate, 5-fluorouracil).